# US 2010/0168202 A1 · Rad 9 as a diagnostic,prognostic,and therapeutic tool for prostate cancer > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2010/0168202 A1 - Document ID: US20100168202A1 - Status: Published application - Kind: A1 - Application number: 12/451,881 - Filed: 2008-06-06 - Published: 2010-07-01 - Earliest claimed: 2007-06-06 - Inventors: Howard B. Lieberman; Aiping Zhu - Web page: https://patentgrep.com/patent/US20100168202A1 ## CPC - C07K 16/18: against material from animals or humans - A61P 35/00: Antineoplastic agents - C07K 16/3069: {Reproductive system, e.g. ovaria, uterus, testes, prostate} - C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)} - C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575) - C12Y 301/11002: Exodeoxyribonuclease III (3.1.11.2) - G01N 33/57555: of the prostate - C12N 2310/111: spanning the whole gene, or a large part of it - C12N 2310/14: interfering nucleic acids [NA] - C12N 2320/31: Combination therapy - C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism - C12Q 2600/118: Prognosis of disease development - G01N 2800/50: Determining the risk of developing a disease - G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES - C12Y: ENZYMES - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract This disclosure provides a method of treating a human subject having a cancer which comprises administering to the subject a nucleic acid so as to inhibit expression of human RAD9 protein in a cell of the cancer so as to thereby treat the human subject. This disclosure also provides methods of assessing gains in prostate cancer therapy and detecting prostate cancer. ## Claims ### Claim 1 A method of treating a subject having a cancer which comprises administering to the subject a nucleic acid which inhibits expression of a human RAD9 gene so as to thereby treat the human subject. ### Claim 2 (depends on 1) The method of claim 1, wherein the cancer is a cancer of the prostate. ### Claim 3 (depends on 1) The method of claim 1, wherein the nucleic acid is, or upon transcription becomes, a short interfering ribonucleic acid. ### Claim 4 (depends on 3) The method of claim 3, wherein the short interfering ribonucleic acid comprises two ribonucleic acid strands, one of which comprises about 15 to about 28 ribonucleotides the sequence of which is complementary to a sequence of consecutive nucleotides present within the human RAD9 gene, and the other of which comprises about 15 to about 28 ribonucleotides, the sequence of which is identical to such sequence of consecutive nucleotides within the human RAD9 gene. ### Claim 5 (depends on 4) The method of claim 4, wherein the sequence of consecutive nucleotides present within the human RAD9 gene comprises AGGCCCGCCAUCUUCACCA (SEQ ID NO:5). ### Claim 6 (depends on 4) The method of claim 4, wherein each strand of the short interfering ribonucleic is 21 nucleotides in length, and wherein the sequence of 19 consecutive nucleotides of one of the strands is complementary to a sequence of 19 consecutive nucleotides present within the human RAD9 gene, and wherein the sequence of the other strand is 21 ribonucleotides in length, the sequence of 19 consecutive nucleotides of which is identical to such sequence of consecutive nucleotides within the human RAD9 gene. ### Claim 7 (depends on 6) The method of claim 6, wherein the two strands of the short interfering ribonucleic acid are base paired for 19 consecutive nucleotides and have a 2-nucleotide overhang at their respective 3′ ends. ### Claim 8 (canceled) ### Claim 9 (canceled) ### Claim 10 (canceled) ### Claim 11 (depends on 2) The method of claim 2, wherein the nucleic acid is administered to the subject by injection into the prostate of the subject. ### Claim 12 (depends on 11) The method of claim 11, wherein the injection into the prostate of the subject is effected via a catheter into the prostate of the subject. ### Claim 13 (depends on 1) The method of claim 1, wherein administering the nucleic acid to the subject is effected by administering the subject a vector comprising the nucleic acid. ### Claim 14 (canceled) ### Claim 15 (canceled) ### Claim 16 (canceled) ### Claim 17 (canceled) ### Claim 18 (canceled) ### Claim 19 (canceled) ### Claim 20 (depends on 1) The method of claim 1, further comprising irradiating the cancer with radiation from a radiation source. ### Claim 21 (canceled) ### Claim 22 (canceled) ### Claim 23 (canceled) ### Claim 24 (canceled) ### Claim 25 (canceled) ### Claim 26 (canceled) ### Claim 27 (canceled) ### Claim 28 (canceled) ### Claim 29 A method of treating a subject having a cancer which comprises administering to the subject an agent which decreases methylation of a human RAD9-encoding nucleic acid in a cell of the cancer so as to thereby treat the subject. ### Claim 30 (depends on 29) The method of claim 29, wherein the agent is 5′-aza-2′ deoxycytidine. ### Claim 31 (depends on 29) The method of claim 29, wherein the agent is administered by injection, catheterization, heat shock or electroporation. ### Claim 32 (depends on 29) The method of claim 29, wherein the cancer is a cancer of the prostate. ### Claim 33 (depends on 32) The method of claim 32, wherein the agent is administered by direct injection or catheterization into a prostate gland of the subject. ### Claim 34 A composition comprising (i) a short interfering nucleic acid directed to a nucleic acid encoding human RAD9 and (ii) a carrier. ### Claim 35 (canceled) ### Claim 36 (depends on 34) The composition of claim 34, further comprising an anti-cancer agent. ### Claim 37 (depends on 34) The composition of claim 34, wherein the anti-cancer agent is a radioactive source. ### Claim 38 (canceled) ### Claim 39 (depends on 36) The composition of claim 36, wherein the anti-cancer agent is an androgen-suppressing drug. ### Claim at position 40 40-57. (canceled)